This protocol is judged by an institutional assessment board, an unbiased team that testimonials any clinical trials involving humans. If a review will involve a Agenda I drug, when the board approves the protocol as ethical, the researchers really have to apply for an investigational new drug (IND) range with the FDA.Together with the doses packa